ADVFN - Advanced Financial Network.
HOME» NYSE » V » VRX Stock Price » VRX Stock News

Valeant Pharma Share News

 Valeant Pharmaceuticals International Stock Price
VRX Stock Price
 Valeant Pharmaceuticals International Stock Chart
VRX Stock Chart
 Valeant Pharmaceuticals International Stock News
VRX Stock News
 Valeant Pharmaceuticals International Company Information
VRX Company Information
 Valeant Pharmaceuticals International Stock Trades
VRX Stock Trades

FTC Seeks Additional Info From Teva, Cephalon Regarding Merger

DOW JONES NEWSWIRES Teva Pharmaceutical Industries Ltd. (TEVA, TEVA.TV) and acquisition target Cephalon Inc. (CEPH) each received a request to provide additional information to the U.S. Federal Trade Commission related to a pending $6.8 billion deal between the firms. Israel-based Teva, which trumped a hostile offer from Valeant Pharmaceuticals International Inc. (VRX) in agreeing to buy Cephalon last month, said it had expected the request. The parties have been cooperating with the FTC staff since shortly after the bid was announced, according to Teva, which said it intends to win clearance "as promptly as possible." Teva on Monday said it continues to expect the deal to be completed in the third quarter, following clearance from U.S. and European regulators, as well as winning approval of Cephalon shareholders. Teva's American depositary shares were recently up 0.4% to $49.35 in after-hours trading. -By John Kell, Dow Jones Newswires; 212-416-2480; [email protected]

Stock News for Valeant Pharma (VRX)
DateTimeHeadline
03/24/201703:02:00Valeant Paid CEO $62.7 Million Total -- WSJ
03/23/201718:45:00Valeant CEO Joseph Papa Was Paid $62.7 Million in 2016 -- 4th...
03/23/201714:44:00Valeant CEO Joseph Papa Was Paid $62.7 Million in 2016 -- 3rd...
03/23/201713:51:00Valeant CEO Joseph Papa Was Paid $62.7 Million in 2016 -- 3rd...
03/23/201712:01:00Valeant CEO Joseph Papa Was Paid $62.7 Million in 2016 -- 2nd...
03/23/201711:35:00Valeant CEO Joseph Papa Was Paid $62.7 Million in 2016 -- Update
03/23/201710:11:00Valeant CEO Joseph Papa Was Paid $62.7 Million in 2016
03/23/201708:05:22Proxy Statement (definitive) (def 14a)
03/21/201716:51:10Current Report Filing (8-k)
03/21/201716:30:00Valeant Completes Refinancing Transactions
03/21/201716:30:00Valeant Completes Refinancing Transactions
03/20/201721:45:00Valeant Announces the Early Results of Tender Offers for Its...
03/20/201721:45:00Valeant Announces the Early Results of Tender Offers for Its...
03/20/201717:00:00Bausch + Lomb And Nicox Announce PDUFA Date For Novel Glaucoma...
03/20/201717:00:00Bausch + Lomb And Nicox Announce PDUFA Date For Novel Glaucoma...
03/17/201716:24:22Current Report Filing (8-k)
03/16/201717:13:47Statement of Changes in Beneficial Ownership (4)
03/16/201717:06:04Statement of Changes in Beneficial Ownership (4)
03/16/201716:43:41Statement of Beneficial Ownership (sc 13d)
03/16/201716:32:58Statement of Changes in Beneficial Ownership (4)

Valeant Pharma and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US